Introduction {#Sec1}
============

Approximately 1% of all the colorectal cancer (CRC) cases are due to familial adenomatous polyposis (FAP), an autosomal dominant CRC predisposition syndrome with a penetrance close to 100% \[[@CR1]\]. The classic FAP phenotype is characterized by the development of multiple (hundreds to thousands) colonic adenomatous polyps at early age \[[@CR2]\]. Moreover, FAP patients frequently develop extra-colonic manifestations, including upper gastrointestinal and desmoids tumors, mandibular osteomas, and hypertrophic pigmentary lesions of the retina \[[@CR3]\]. Typically, FAP arises on heterozygous germline variants in the Adenomatous Polyposis Coli (*APC*) tumor-suppressor gene located on chromosome region 5q21--22 \[[@CR4]\]. The *APC* gene encodes for a protein that is critically involved in the canonical Wnt signaling pathway, the activation of which leads to β-catenin nuclear translocation and intestinal epithelium hyperproliferation \[[@CR5]\]. Most inactivating *APC* germline variants are frameshift or nonsense; in addition, the *APC* gene could be inactivated through promoter hypermethylation or large deletions \[[@CR6], [@CR7]\]. A high frequency of de novo*APC* variants (10--25%), generally affecting the "mutation cluster region"(MCR; codons 1286--1513) \[[@CR6]\], has been reported in FAP patients \[[@CR8], [@CR9]\]. Moreover, somatic mosaicism in the *APC* gene has been described in a small subset of FAP cases \[[@CR10]--[@CR12]\].

Biallelic inactivation of the MutY homolog (*MutYH*) gene causes an autosomal recessive form of polyposis, characterized by the development of few adenomas and progression to CRC at an older age than classic FAP \[[@CR13]\]. Variants in this gene were found in \~20% of cases with attenuated polyposis \[[@CR14]\]. The *MutYH* gene, located on chromosome region 1p34.3--1p32.1, encodes a protein involved in the Base Excision Repair (BER) pathway that prevents DNA damage induced by 8-oxo-7, 8-dihydro-2′-deoxyguanosine \[[@CR13]\]. In addition, rare forms of colorectal polyposis are caused by variants in *POLE*, *POLD1*, and *NHTL1* genes \[[@CR15]--[@CR17]\]. *POLE* and *POLD1* genes encode for the main catalytic and proofreading subunits of polymerase ε and δ enzyme complex, critically involved in DNA replication fidelity \[[@CR18]\]. *NTHL1* gene encodes for a member of the BER pathway that removes oxidized pyrimidines and ring-opened purines \[[@CR19]\]. Recently, biallelic germline variants in the *MSH3* gene, a member of the DNA mismatch repair (MMR) system, has been reported as an additional genetic cause of colorectal polyposis \[[@CR20]\].

However, to date, in \~30--50% of cases, the genetic defect responsible for the onset of colorectal polyposis remains unknown \[[@CR21]\], leading to uncertainties in establishing proper clinical management and risk for relatives. Thus, the main goal of this study was to identify the genetic defect in a set of adenomatous polyposis patients with no germline variants in known predisposing genes, aiming to provide an appropriate diagnosis and treatment. Through a rigorous selection of candidate patients, we were able to identify *APC* mosaicism as the main cause of colorectal polyposis in 50% of the enrolled patients (4 out of 8), and to define a new oligogenic inheritance model that could explain an *APC*-independent polyposis in one patient.

Methods {#Sec2}
=======

Patients and data collection {#Sec3}
----------------------------

From January 2004 to March 2016, 56 patients with a clinical and histological diagnosis of adenomatous colorectal polyposis underwent genetic counseling at the Familial Colorectal Cancer Clinic of the Sant'Orsola-Malpighi Hospital (Bologna, Italy). As shown in Fig. [1](#Fig1){ref-type="fig"}, 29 (51.8%) patients were found to carry a causative variant in *APC* (*n* = 22) or *MutYH* (*n* = 7) genes. Among patients with no conclusive genetic diagnosis, those with 20 or more adenomatous polyps by 35 years of age or with 50 or more adenomatous polyps by 55 years of age were considered eligible for this study. Polyps were histologically characterized by an expert pathologist (T.B.). Patients with polyps histologically different from adenomas were excluded. Of the 11 eligible patients, 8 accepted to participate and provided their informed written consent. None of the enrolled patients had a family history of adenomatous polyposis. Clinico-pathological characteristics of enrolled patients are reported in Table [1](#Tab1){ref-type="table"}. For all patients, Formalin-Fixed Paraffin-Embedded (FFPE) tissues (adenomatous polyps and normal mucosa) from different endoscopic sessions and a blood sample were obtained. For five patients (P1--P4, P8), fresh adenomatous polyps (\<5 mm) and normal colonic mucosa samples were also collected during colonoscopy, and stored in RNAlater® (Thermo Fisher Scientific, MA, USA) until DNA extraction. For patients with *APC* mosaicism, hair follicles and saliva samples were also collected. When possible, peripheral blood samples from probands' parents and/or siblings (Table [1](#Tab1){ref-type="table"}) were obtained. Peripheral blood samples from two healthy subjects were obtained and DNA was used as reference samples for some analyses. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the S.Orsola-Malpighi Hospital, Bologna, Italy.Fig. 1Flowchart of the patients' mutational screening, selection, and enrollmentTable 1Clinico-pathological characteristics of enrolled patients (*n* = 8)PatientGenderAge^a^ (Years)N PolypsAdditional clinical manifestationsParents/siblings^b^P1F32\>50NoYesP2M24\>100NoYesP3F47\>150Duodenal adenomas; Bilateral sensorineural hearing loss; Diabetes mellitus type IIYesP4M23\>20NoYesP5M29\>20Proctocolectomy 2 synchronous adenocarcinomasYesP6M54\>50Proctocolectomy 2 synchronous adenocarcinomasNoP7M55\>50Urothelial cancer; Total colectomyNoP8F40\>50Sub-total colectomyYes^a^Age at diagnosis^b^Available blood samples

DNA extraction {#Sec4}
--------------

DNA from peripheral blood, saliva, and hair follicles was isolated using the QIAmp^®^ Blood Mini Kit, although DNA from fresh colonic tissues was obtained using the AllPrep^®^ DNA/RNA/Protein Mini kit (Qiagen, Milan, Italy) according to the manufacturer's protocols. DNA from FFPE tissues was extracted using the Maxwell^®^16 FFPE Plus LEV DNA Purification kit (Promega, Milan, Italy) after macrodissection. DNA concentration was measured using the Nanodrop 1000 spectrophotometer (Thermo Scientific, USA).

*APC* variant screening and mosaicism detection {#Sec5}
-----------------------------------------------

For *APC* variant screening, the entire coding region of the *APC* gene (RefSeq NM_000038.5), as well as promoters 1A (RefSeq U02509.1) and 1B (RefSeq D13981.1), were sequenced by Sanger sequencing on DNA extracted from one fresh adenomatous polyp, except for patient P1, where two polyps where analyzed. Any *APC* variant identified in a polyp was checked on FFPE DNA samples of at least four independent adenomatous polyps and two samples of normal mucosa. Primer sequences and annealing temperatures are reported in Supplementary Table S[1A](#MOESM2){ref-type="media"}. A condition of mosaicism was assumed if the same pathogenic variant was present in at least four independent FFPE adenomatous polyps.

*APC* mosaicism extension evaluation {#Sec6}
------------------------------------

To investigate the *APC* mosaicism extension within the three germ layers, DNA extracted from fresh and available FFPE colonic tissues (endoderm), peripheral blood lymphocytes (mesoderm), and hair follicles and saliva (ectoderm) was analyzed with Sanger sequencing (as reported above) and/or the QuantStudio^TM^ 3D Digital PCR (dPCR) system (ThermoFisher Scientific). For dPCR, rare variants were analyzed using Taqman® custom SNPs genotyping assays (Supplementary [Methods](#MOESM1){ref-type="media"} and Table S[2](#MOESM3){ref-type="media"}). The rare mutant allele frequency was obtained by dividing the number of copies per microlitre of the mutant allele by the total number of copies per microlitre of the wildtype plus the mutant alleles. The Limit of Detection (LoD) for each Taqman® custom SNPs genotyping assay was assessed by analyzing two genomic DNA samples from healthy subjects. For the Taqman probe c.637C\>T (Supplementary Table S[2](#MOESM3){ref-type="media"}), the LoD was 0.2%, while for the other assays it was 0%. dPCR reactions were performed in triplicate, except for FFPE derived samples that were tested in duplicate for paucity of DNA.

*APC* second hit analysis {#Sec7}
-------------------------

In order to investigate whether an epigenetic, genomic (deletions/duplications), or mutational second hit in the *APC* gene had occurred in patients with proved *APC* mosaicism (*n* = 4), methylation of the *APC* promoter 1A (RefSeq U02509.1), Multiplex Ligation Probe Amplification (MLPA), and *APC* hot spot codons analyses were performed. For methylation analysis, DNA extracted from fresh adenomatous polyps was treated with sodium bisulfite using EZ DNA Methylation-Gold^TM^ (ZymoResearch, Freiburg, Germany), according to the manufacturer's protocols, and analyzed by bisulfite sequencing. Primers amplifying a sequence located between −327 and −38 from the transcriptional start codon of the promoter 1A and containing 21 CpG dinucleotides were designed using MethPrimer software \[[@CR22]\]. MLPA was conducted on DNA extracted from fresh adenomatous polyps and normal mucosa using the SALSA MLPA *APC* probemix (P043, MRC-Holland, Amsterdam, The Netherlands). All data were analyzed using the Coffalyser.Net software (MRC-Holland), which generates a relative probe ratio from the comparison between adenomatous polyps and normal mucosa. A probe ratio below 0.7 or above 1.3 was regarded as indicative of a heterozygous deletion or duplication, respectively. Variants in *APC* gene hot spot codons (1061, 1309, and 1450) were analyzed by Sanger sequencing. Primer sequences and annealing temperatures are reported in Supplementary Table S[1A](#MOESM2){ref-type="media"}.

*BRAF*, *KRAS,* and *CTNNB1* analysis {#Sec8}
-------------------------------------

Somatic variants in *BRAF* (c.1799T\>A p.(Val600Glu); RefSeq NM_004333.4), *KRAS* (codons 12--13; RefSeq NM_004985.4), and *CTNNB1* (exon 3; RefSeq NM_001904.3) genes were analyzed by Sanger sequencing on available FFPE adenomatous polyps as reported above. Primer sequences and annealing temperatures are reported in Supplementary Table S[1B](#MOESM2){ref-type="media"}.

Whole exome sequencing {#Sec9}
----------------------

Whole Exome Sequencing (WES) was performed on genomic DNA isolated from peripheral blood samples of probands and parents (and/or siblings). As DNA from parents of patients P6 and P7 was not available, we conducted WES on probands only in these patients. A DNA library was prepared using Nextera^®^ DNA Library Kit (Illumina Inc. USA) and sequenced on an Illumina HiSeq2000 platform. The obtained reads were aligned to the reference genome GRCh37/hg19 using the Burrow--Wheeler Aligner software \[[@CR23]\]. The alignments were stored in the BAM file and processed using GATK and ANNOVAR softwares \[[@CR24], [@CR25]\]. Whenever possible, the variants were filtered with the parents/siblings, considering both a dominant and a recessive autosomal inheritance pattern using DeNovoGear and Gemini softwares \[[@CR26], [@CR27]\]. Only those variants whose prediction showed a strong effect on gene function were considered for downstream analysis: (1) frameshift variants (insertions/deletions across the coding sequence); (2) variants located within 5 bp from the intron--exon junctions of coding exons (canonical splice-site); and (3) non-synonymous single-nucleotide variants (nonsense and missense). The variants with Minor allele frequency (MAF) ≥0.01 based on data from dbSNP \[[@CR28]\], 1000 Genomes Project \[[@CR29]\], NHLBI Exome Sequencing project (<http://evs.gs.washington.edu/EVS/>), Exome Aggregation Consortium \[[@CR30]\], and in-house database (264 patients with non-cancer disorders) were filtered out. Regarding the missense variants, only those with possible or probable deleterious effect according to three in-silico prediction tools (PolyPhen2, score ≥0.85; SIFT, score ≤0.5; CADD score ≥3) were selected \[[@CR31]--[@CR33]\]. These variants were further filtered considering the function and expression of the candidate genes. For this reason OMIM \[[@CR34]\], Human Protein Atlas \[[@CR35]\], COSMIC \[[@CR36]\], Colorectal Cancer Atlas \[[@CR37]\], and KEGG pathway \[[@CR38]\] databases were consulted. The pathogenic relevance of the variants was further explored by evaluating their genetic intolerance to functional variations according to the Residual Variations Intolerance score \[[@CR39]\]. All selected variants were validated through Sanger sequencing. For patients P5, P6, and P7, as fresh colonic tissues were not available due to previous surgical procedures (proctocolectomy or colectomy), WES was also performed on DNA from one FFPE adenomatous polyp for each patient to identify somatic *APC* variants. For any candidate variant identified by WES, somatic loss of heterozygosity (LOH) was performed (Supplementary [Methods](#MOESM1){ref-type="media"}).

All the variant and phenotype data have been submitted to the LOVD database (<https://databases.lovd.nl/shared/genes/APC>; variants IDs 0000174613-0000174623 and 0000174632).

Results {#Sec10}
=======

Somatic APC mosaicism in patients with unexplained colorectal adenomatous polyposis {#Sec11}
-----------------------------------------------------------------------------------

Among the 56 patients with a clinical diagnosis of polyposis, 8 had no causative germline variants in *APC* and/or *MutYH* genes and fulfilled the inclusion criteria. These patients were enrolled (Fig. [1](#Fig1){ref-type="fig"}) and evaluated for *APC* mosaicism. A flowchart reporting somatic *APC* variants screening is shown in Fig. [2](#Fig2){ref-type="fig"}. The initial investigation of the whole *APC* gene for somatic variants was performed in one polyp sample for each patient, except for patient P1 where two polyps were analyzed.Fig. 2Flowchart of *APC* mosaicism evaluation in enrolled patients. The initial screening of the whole *APC* gene was carried out in one adenomatous polyp sample for each patient, except for patient P1 where two polyps were analyzed

Seven patients (P1--P7) had a variant in the *APC* gene (Table [2](#Tab2){ref-type="table"} and Supplementary Table S[3](#MOESM4){ref-type="media"}). No pathogenic variants in the *APC* gene were found in colonic adenomatous polyps of patient P8 carrier of a germline in-frame deletion in the *APC* gene c.3468_3470delAGA p.(Glu1157del) of unknown significance (VUS). Analysis of multiple adenomatous polyps unveiled a condition of *APC* mosaicism in 50% of patients (P1--P4) with unexplained adenomatous polyposis (Table [2](#Tab2){ref-type="table"}).Table 2*APC* variants and rare variant allele frequencies in patients with mosaicismPatientVariantTissueLocalizationSangerdPCR (%)P1c.637C\>T p.(Arg213\*)Fresh NMn.a.Wt0.37Fresh Polyp 1n.a.Variant19.2Fresh Polyp 2n.a.Variant12.2FFPE NM 1Hepatic flexure/transverse colonVariantn.a.FFPE NM 2Transverse colonWtn.a.FFPE NM 3Sigmoid colonWt1.96FFPE Polyp 1Hepatic flexure/transverse colonVariantn.a.FFPE Polyp 2Hepatic flexure/transverse colonVariantn.a.FFPE Polyp 3Splenic flexure/discending colonVariantn.a.FFPE Polyp 4Transverse colonVariantn.a.FFPE Polyp 5Transverse colonVariant26.5FFPE Polyp 6Sigmoid colonVariant27.3FFPE Polyp 7Sigmoid colonVariantn.a.P2c.2626C\>T p.(Arg876\*)Fresh NMn.a.Wt0Fresh Polyp 1n.a.Variant21.1Fresh Polyp 2n.a.Variant8.9FFPE NM 1Ascending colon/hepatic flexureVariantn.a.FFPE NM 2Sigmoid colonVariantn.a.FFPE NM 3Sigmoid colonn.a.9.7FFPE NM 4Sigmoid colonn.a.0FFPE Polyp 1Ascending colon/hepatic flexureVariant17.6FFPE Polyp 2Ascending colon/hepatic flexureVariantn.a.FFPE Polyp 3Sigmoid colonVariantn.a.FFPE Polyp 4Sigmoid colonVariantn.a.FFPE Polyp 5Sigmoid colonVariant33.4FFPE Polyp 6Sigmoid colonVariantn.a.P3c.4393_4394delAG p.(Ser1465Trpfs\*3)Fresh NMn.a.Wt0Fresh Polypn.a.Variant18.5FFPE NM 1Sigmoid colon-rectumWt0.9FFPE NM 2Sigmoid colon-rectumn.a.4.5FFPE Polyp 1Sigmoid colon-rectumVariantn.a.FFPE Polyp 2Sigmoid colon-rectumVariant30.8FFPE Polyp 3Sigmoid colon-rectumVariantn.a.FFPE Polyp 4Sigmoid colon-rectumVariant18.4FFPE Polyp 5Sigmoid colon-rectumVariantn.a.P4c.3927_3931delAAAGA p.(Glu1309Aspfs\*4)Fresh NMAscending colonWt0Fresh PolypAscending colonVariant26.4FFPE NM 1Ascending colonWt6.6FFPE NM 2Approx 45 cm ab anoWt0FFPE Polyp 1Ascending colonVariant26.4FFPE Polyp 2Ascending colonVariantn.a.FFPE Polyp 3Hepatic flexureVariant24.8FFPE Polyp 4Approx 45 cm ab anoVariant18.7*NM* normal mucosa, *Polyp* adenomatous polyp, *FFPE* Formalin-Fixed Paraffin-Embedded, *n.a.* not analyzed, *Wt* wildtype, *dPCR* digital PCR, *APC* variants description refers to RefSeq NM_000038.5

To establish *APC* mosaicism extent in these patients, further tissues (normal colonic mucosa, blood, hair follicles, and saliva) were analyzed through Sanger sequencing and dPCR. Importantly, dPCR proved to be more sensitive compared to Sanger sequencing. Indeed, dPCR allowed us to identify *APC* variants in fresh and FFPE normal mucosa samples of patient P1 and in one normal mucosa sample of patients P2, P3, and P4, despite being present at low frequency. In addition, while mosaicism was confined to the colon in three out of four patients (P1, P2, and P4), in one patient (P3) an extension to the duodenum (52%) and saliva was also found by dPCR (0.25%). We also excluded the involvement of other known predisposing colorectal polyposis genes, including *POLE*, *POLD1*, *NTHL1,* and *MSH3*, by WES on DNA from peripheral blood.

APC second hit in mosaic patients {#Sec12}
---------------------------------

To identify whether patients with *APC* mosaicism also harbored a second hit in the *APC* gene, we first analyzed hot spot codons for somatic inactivating variants, finding a second hit in three out of four patients. In patient P1, we identified a frameshift variant affecting the hot spot codon 1309 (c.3927_3931delAAAGA p.(Glu1309Aspfs\*4)) in one FFPE adenoma sample and another frameshift variant (c.4187_4188delTT p.(Phe1396\*)) in another two different FFPE adenoma samples. In patient P2, a variant affecting the hot spot codon 1450 (c.4348C\>T p.(Arg1450\*)) was found in 1/6 FFPE adenoma samples, while patient P3 harbored a second hit in the codon 1027 (c.3081_3085delinsGAG p.(Tyr1027\*)) in 2/5 FFPE adenoma samples. In patient P4, no hot spot mutational events were found. Neither aberrant methylation of promoter 1A nor duplications/deletions in the *APC* gene coding region were found in any patient.

Variants in known CRC predisposing genes {#Sec13}
----------------------------------------

To evaluate the presence of additional somatic mutational events in other genes critically involved in CRC development, we analyzed *BRAF*, *KRAS*, and *CTNNB1*. All patients were wildtype for *BRAF* and *CTNNB1*. Patient P2 showed two heterozygous variants in *KRAS* (c.35G\>A p.(Gly12Asp) and c.38G\>A p.(Gly13Asp)) in different adenomatous polyps, while patients P5 and P7, both had a heterozygous KRAS variant in one polyp (P5: c.34G\>A p.(Gly12Ser); P7: c.35G\>A p.(Gly12Asp)).

WES analysis and oligogenic inheritance in rare variants {#Sec14}
--------------------------------------------------------

Enrolled patients had no family history of adenomatous polyposis, suggesting that *APC* somatic mosaicism, de novo variants, biallelic variants (recessive inheritance), or polygenic inheritance could explain their clinical phenotype. Thus, to identify genetic defects occurring in patients without *APC* mosaicism or causative *APC* variant (*n* = 4) or to identify potential additional pathogenic variants in patients with *APC* mosaicism, WES was performed on DNA from peripheral blood. For patients P1--P7, no additional or causative polyposis variants were found. Intriguingly, WES analysis of patient P8, a carrier of the VUS c.3468_3470delAGA p.(Glu1157del) (rs386833391; MAF not available) in the *APC* gene, showed a missense variant c.923G\>A p.(Gly308Glu) (rs113561019) in the *8-Oxoguanine DNA glycosilase* (*OGG1* RefSeq NM_016829.2), a splicing variant c.2212--1G\>C (rs4150000) in the *Exonuclease 1* (*EXO1* RefSeq NM_130398.3 NG_029100.1), and a missense variant c.6743A\>G p.(Asn2248Ser) (rs376729696) in the *DNA Polymerase theta* (*POLQ* RefSeq NM_199420.3) genes. The results of the prediction tools for the missense and splicing variants and MAF values are reported in Supplementary Table S[4](#MOESM5){ref-type="media"}. All identified variants were heterozygous and no LOH was found. However, since we performed only Sanger sequencing for the regions containing the variants, we cannot rule out other kinds of second hits. Importantly, segregation analysis showed that the co-occurrence of two of these variants was not sufficient to cause the phenotype being present in all unaffected members of the family (Fig. [3](#Fig3){ref-type="fig"}). Thus, we can hypothesize that the combination of these four variants could be responsible for polyposis development in patient P8.Fig. 3Pedigree of patient P8. Variants are reported in proband and in family members. All relatives, except the father (I.1), underwent colonoscopy. Variants description refers to the following reference sequences: *APC* NM_000038.5; *OGG1* NM_016829.2; *EXO1* NM_130398.3 NG_029100.1; and *POLQ* NM_199420.3

Discussion {#Sec15}
==========

A considerable proportion of colorectal adenomatous polyposis cases remain genetically unsolved. In this study, we aimed to identify the genetic cause of adenomatous polyposis in patients with no germline variants in known predisposing genes. *APC* mosaicism is emerging as an important mechanism for polyposis onset \[[@CR10]--[@CR12], [@CR40]\]. Noteworthy, we found somatic *APC* mosaicism in 50% of the enrolled patients. We believe that although our restrictive inclusion criteria (no family history of polyposis, age at diagnosis, and number of adenomatous polyps) reduced the number of eligible patients, they allowed us to efficiently intercept *APC* mosaic patients. Indeed, previously published studies found a lower percentage of *APC* mosaicism \[[@CR10]--[@CR12]\], and only one recent study identified an *APC* mosaicism rate corresponding to \~50% \[[@CR41]\]. It is to note that the percentage of identification of mosaic cases depends on the inclusion criteria of the study and, if mainly attenuated polyposis cases are included, as in this study, the detection rate seems to be higher.

Mosaicism extension depends on the time when the variant occurs during embryogenesis. Interestingly, in our study, mosaicism was confined to the colon in three patients, suggesting that the first mutational event affected the endoderm. Conversely, in one patient with a more complex clinical phenotype (\>150 colonic adenomas, duodenal adenomas, bilateral sensorineural hearing loss, and diabetes mellitus type II), mosaicism was also extended to the duodenum and saliva, involving both the endodermal and ectodermal layers. In addition, we found no variants in peripheral blood and hair follicles in any patient. Moreover, we checked the positions of *APC* mosaic variants in WES data obtained from leukocyte DNA and we did not find any variant alleles (based on a coverage of 45--147 reads).

In this study the *APC* mosaicism search was performed in a large number of colonic samples and additional tissues. Interestingly, the *APC* variants could not be detected in some normal mucosa colonic samples, as reported also by Jansen and colleagues \[[@CR41]\]. We speculate that this pattern might suggest a condition of intra-organic mosaicism in the colon. Moreover, we believe that the analysis of multiple adenomatous polyps should be recommended as a future direction for more definitive studies on mosaicism identification. Noteworthy, our data highlight the importance of using highly sensitive technologies, such as dPCR, in order to increase the likelihood of detecting *APC* mosaicism extension. In particular, if only gastrointestinal tissues are affected by *APC* mosaicism, but not peripheral blood or ectodermal-derived tissues, the risk of transmission to the offspring is low.

Intriguingly, WES analysis allowed us to identify rare variants in *OGG1*, *EXO1*, and *POLQ* genes in a patient carrying the germline *APC* VUS c.3468_3470delAGA p.(Glu1157del). Importantly, we described, for the first time, that the combination of these four variants represents an oligogenic inheritance pattern that may explain colorectal polyposis in this patient. These variants have already been described \[[@CR42]--[@CR46]\]. *OGG1* and *EXO1* are involved in the BER and MMR pathways and could act as low-penetrance alleles contributing to adenomatous polyposis and CRC progression \[[@CR43]--[@CR46]\], while *POLQ* is implicated both in maintaining genomic stability and BER \[[@CR47], [@CR48]\]. The combined effect of variants in *APC*, *EXO1*, and in the endonuclease *FEN1* was previously found to promote gastrointestinal carcinogenesis in mice \[[@CR49]\]. In addition, a combination of germline variants in *OGG1* and *MutYH* genes has been reported as a model of digenic inheritance for early colorectal adenomas and cancer development in one patient \[[@CR44]\].

Although our results confirm the relevance of *APC* gene mosaicism as an underlying cause of colorectal polyposis, we acknowledge that this study has some limitations. First, the number of patients is small. Second, we cannot exclude the remote possibility of additional causative variants in other genes not investigated in this study. Third, due to the paucity of available material, *APC* second hit analysis involved hot spot codons only. Fourth, since the initial analysis of the whole *APC* gene for somatic variants was performed only in one adenomatous polyp for each patient (except for patient P1), we might have missed *APC* mosaicism in the other four patients because the "variant of interest" could be below the detection threshold of Sanger sequencing/WES in the polyp analyzed, but maybe in other polyps it would be detectable.

In conclusion, our study provides new insights for the genetic characterization and screening of patients with unexplained adenomatous polyposis. In view of our findings, for a more accurate assessment of patients carrying *APC* mosaicism and of their offspring, we highly recommend the collection and testing of multiple adenomas, normal-appearing colonic mucosa, and other biological samples. We believe that larger cohorts and more studies are needed to explore the percentage of *APC* mosaic cases more comprehensively. Finally, we propose a new oligogenic inheritance model to explain an unsolved case of polyposis.
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